ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye
SAN FRANCISCO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- ProLynx and Daiichi Sankyo Company, Limited, announced today the publication of a paper in the journal TVST entitled “A controlled release system for long-acting intravitreal delivery of small molecules”. In this work, they described a technology to extend the intravitreal half-life of small molecule drugs to rival the intravitreal half-lives of macromolecules such as antibodies and PEGylated aptamers.
Intravitreal (IVT) injection is an important drug delivery modality for many diseases of the eye. IVT injection minimizes systemic exposure and allows intraocular drug exposures not otherwise achievable. However, because IVT therapy is an invasive procedure that often requires long-term serial injections, IVT drugs require long IVT half-lives and dosing intervals.
In the past, IVT injections of small molecule therapeutics have been impractical for treatment of chronic eye diseases because they have short half-lives in the vitreous and require frequent injections. In the present work a small molecule drug was attached to a nanomolecular 40kDa PEG via a cleavable linker. The large nanomolecule maintains the small molecule in the vitreous for long periods, and the attached drug is slowly released by a self-cleaving linker. Using this approach, the half-life of a small molecule complement factor D inhibitor in the rabbit eye was prolonged 10-fold. It was posited that the technology could maintain a small molecule drug in the human vitreous for periods comparable to macromolecular drugs, requiring intravitreal injections at about one month intervals.
Daniel Santi, co-founder and President of ProLynx, stated “This study reports an entirely new approach for increasing the intravitreal half-lives of small molecule therapeutics; a potent small molecule with an appropriate therapeutic window should be administrable by intravitreal injections in the human at once-monthly intervals.”
About ProLynx: ProLynx LLC is a privately held biotechnology company located in San Francisco, CA, developing proprietary controlled release systems for long-acting delivery of small molecules, peptides and proteins. The company applies its technology to extend half-lives and improve properties of the drug candidates of pharmaceutical companies as well as to enhance properties of off-patent therapeutics. ProLynx has a monthly GLP-1 receptor agonist and a subcutaneous long-acting octreotide in its pre-clinical portfolio, and a DNA-damage response enhancer, PEG~SN-38, in Phase 1 clinical trials. For more information, please visit: www.ProLynxllc.com.
About Daiichi Sankyo: Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address unmet medical needs of patients. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo draws upon a rich legacy of innovation and a robust pipeline of new medicines. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology, and new horizon areas such as pain management, neurodegenerative diseases, heart and kidney diseases, and rare diseases. For more information, please visit: www.daiichisankyo.com.
BD@ProLynxllc.com or email@example.com 805-558-0361
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Wencor Group Announces Acquisition of Silver Wings14.11.2018 15:58 | Pressemelding
Peachtree City, GA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- WENCOR GROUP ANNOUNCES ACQUISITION OF SILVER WINGS Peachtree City, GA (November 8th, 2018) -- Wencor Group (“Wencor”), a leading solutions provider to the aerospace aftermarket, today announced the acquisition of Silver Wings Aerospace, a certified 145 repair station specializing in electric power and hydraulic component repair with unique capabilities in Used Serviceable Material (“USM”). Terms of the transaction were not disclosed. "We are pleased to welcome Silver Wings leadership and their employees to the Wencor team. This partnership aligns with our strategy to drive ATA chapter depth and proprietary component repair capabilities while enhancing our presence in USM. We are thrilled to partner with great entrepreneurs like Eddie Montalvo and Sean Beaubien and look forward to working with the rest of their team who have developed a high quality customer-focused MRO business" said Chris Curtis, Chief Executive Officer of Wencor G
Kofax Advances Enterprise-Wide Deployment of Next-Generation Robotic Process Automation to Rapidly and Exponentially Scale the Digital Workforce14.11.2018 14:00 | Pressemelding
Kofax RPA Powers Industry’s First Single-Vendor Intelligent Automation Offering; Free 12-Month Trial Provides Time to Build, Deploy and Measure Results with No Commitment IRVINE, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Kofax ®, a leading supplier of Intelligent Automation software to automate and digitally transform end-to-end business processes, today announced Kofax RPA’s next-generation robotic process automation (RPA) capabilities that leverage artificial intelligence (AI) and machine learning (ML). Providing “out-of-the-box” functionality, Kofax is first to market with a comprehensive, single-vendor, single-platform, Intelligent Automation solution. “Early adopters of RPA have experienced the many benefits in shifting human labor from ‘data gatherer’ to ‘data user’ roles. Increased productivity helps them remain on track for profitable growth, improved customer service and significant competitive advantage,” said Reynolds C. Bish, Chief Executive Officer of Kofax. “These excepti
Biome Grow subsidiary, Highland Grow, receives license to sell to other licensed producers from Health Canada14.11.2018 14:00 | Pressemelding
TORONTO, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE:BIO) (Frankfurt:6OTA) is pleased to announce its Nova Scotia-based subsidiary, Highland Grow Inc. (“Highland Grow”), has received its license to sell to other licensed producers from Health Canada in accordance with subsection 11(5) of the Cannabis Regulations. "This license gives the company additional commercial sales avenues and flexibility for our high quality cannabis products and services that are ready for our customers," said Khurram Malik, CEO of Biome. The Health Canada license, issued in accordance with the Cannabis Act and Cannabis Regulations, specifically grants Highland Grow the ability to: possess cannabis; obtain dried cannabis, fresh cannabis, cannabis plants or cannabis plant seeds by cultivating, propagating, and harvesting cannabis; and, to sell cannabis in accordance with subsection 11(5) of the Cannabis Regulations. With this license, Highland Grow is positioned to sell and
Colliers International Expands in South Florida14.11.2018 13:30 | Pressemelding
Acquisition of Preeminent Brokerage and Management Firm Strengthens Leadership and Service Offering TORONTO and MIAMI, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Leading global commercial real estate services and investment management firm Colliers International Group Inc. (NASDAQ and TSX: CIGI) today announced the acquisition of Continental Real Estate Companies Commercial Properties Corp. (“CREC”), a market-leading commercial real estate services firm specializing in property management, project management and sales and lease brokerage. Founded in 1989 by Warren Weiser and Carol Greenberg Brooks, this acquisition brings an extensive portfolio of more than 12.6 million square feet of office, industrial and retail space in Florida and more than 100 professionals operating from three offices throughout the state to Colliers. Terms of the transaction were not disclosed. “This strategic acquisition positions Colliers as the top management and retail brokerage firm in the vibrant South Florida mark
ADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting14.11.2018 13:30 | Pressemelding
New clinical data highlight potential of novel pyrrolobenzodiazepine-based antibody drug conjugates for the treatment of relapsed or refractory lymphomas LAUSANNE, Switzerland, Nov. 14, 2018 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that data from Phase I clinical trials of ADCT-402 (loncastuximab tesirine) and ADCT-301 (camidanlumab tesirine) have been selected for oral and poster presentations at the 60th American Society of Hematology (ASH) Annual Meeting, which is being held December 1-4 in San Diego. Jay Feingold, MD, PhD, Chief Medical Officer and Senior Vice President of Clinical Development at ADC Therapeutics, said, “We look forward to sharing updated data from our first-in-human clinical trials of ADCT-402 and ADCT-301 in multiple subtypes of lymphoma at the 2018 ASH Annual Meeting. Interim data show that ADCT-402, which targets CD
Major telco company partners with Vricon to accelerate 5G rollouts across the USA14.11.2018 13:00 | Pressemelding
Vricon supports major U.S. telecommunications firm with high-resolution 3D geodata for urban and suburban regions across the United States McLean, VA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Vricon is pleased to announce that a major U.S. telecommunications company recently acquired Vricon’s high-resolution 3D geodata to support large-scale 5G telecommunications network planning and design. Under the multimillion-dollar contract, Vricon will provide the firm with 3D data of urban and suburban population centers across the United States. The company is leveraging Vricon’s recent innovations in mapping to accelerate 5G infrastructure planning nationwide. 5G increases the need for accurate, high-resolution geodata. Vricon’s unique big-data solution uses the world’s largest archive of 50cm commercial satellite imagery; the solution is built using automated 3D modeling algorithms that create cost-effective, scalable geodata. By adopting Vricon’s unique mapping technology, telecommunications compa
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom